TY - JOUR
T1 - Who treats lung cancer? Results from a global survey
AU - Komiya, Takefumi
AU - Mackay, Christine B.
AU - Chalise, Prabhakar
N1 - Publisher Copyright:
© 2017 The Japanese Respiratory Society
PY - 2017/9
Y1 - 2017/9
N2 - Background In most Western nations, the medical oncologist plays a significant role in the administration of systemic therapy for lung cancer. In Japan however, treatment for lung cancer has historically been provided by pulmonologists and thoracic surgeons. A comparison of the management of advanced disease between Japan and other nations has not been described. Methods An online, self-administered, international survey was sent to 3907 active members of the American Society of Clinical Oncology. Eligible participants were degreed physicians who prescribed systemic agents for adult cancer treatment within the past five years. Results In total, 281 respondents answered the questions regarding management of lung cancer. Thorough analysis demonstrated that pulmonologists play a significant role in Japan and the Netherlands, where the role of oncologic specialists is not well established. Of note, all the respondents from the Netherlands reported that pulmonary medicine primarily manages systemic chemotherapy in stage IV, adjuvant chemotherapy, and targeted therapy. Conclusion We found there are several nations where non-oncologic specialists play a critical role in the systemic treatment of lung cancer. We expect this practice pattern to continue until the global adoption of the oncologic specialty role.
AB - Background In most Western nations, the medical oncologist plays a significant role in the administration of systemic therapy for lung cancer. In Japan however, treatment for lung cancer has historically been provided by pulmonologists and thoracic surgeons. A comparison of the management of advanced disease between Japan and other nations has not been described. Methods An online, self-administered, international survey was sent to 3907 active members of the American Society of Clinical Oncology. Eligible participants were degreed physicians who prescribed systemic agents for adult cancer treatment within the past five years. Results In total, 281 respondents answered the questions regarding management of lung cancer. Thorough analysis demonstrated that pulmonologists play a significant role in Japan and the Netherlands, where the role of oncologic specialists is not well established. Of note, all the respondents from the Netherlands reported that pulmonary medicine primarily manages systemic chemotherapy in stage IV, adjuvant chemotherapy, and targeted therapy. Conclusion We found there are several nations where non-oncologic specialists play a critical role in the systemic treatment of lung cancer. We expect this practice pattern to continue until the global adoption of the oncologic specialty role.
UR - http://www.scopus.com/inward/record.url?scp=85027411311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027411311&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2017.07.002
DO - 10.1016/j.resinv.2017.07.002
M3 - Article
C2 - 28942886
AN - SCOPUS:85027411311
SN - 2212-5345
VL - 55
SP - 308
EP - 313
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 5
ER -